Baxter International Inc. (NYSE:BAX) Files An 8-K Results of Operations and Financial Condition

Baxter International Inc. (NYSE:BAX) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

Story continues below

On January31, 2019, Baxter International Inc. (the Company) issued an earnings press release for the quarterly and twelve month periods ended December31, 2018. The press release, including attachments, is furnished as Exhibit 99.1 to this report.

The press release furnished as Exhibit 99.1 contains financial measures that are not calculated in accordance with generally accepted accounting principles (GAAP). The non-GAAP financial measures include adjusted income from continuing operations, adjusted diluted earnings per share from continuing operations, adjusted operating income, adjusted other operating income, adjusted other income, net, adjusted gross margin, adjusted marketing and administrative expenses, adjusted research and development expenses, adjusted pre-tax income from continuing operations and adjusted income tax expense, each excluding special items, as well as constant currency sales, operational sales and free cash flow. Special items are excluded because they are highly variable, difficult to predict or unusual and of a size that may substantially impact the Company’s reported operations for a period. Certain of those items represent estimates based on information reasonably available at the time of the press release. Future events or new information may result in different actual results. Additionally, intangible asset amortization is excluded as a special item to facilitate an evaluation of current and past operating performance.

Net sales amounts are presented on a constant currency basis. This measure provides information on the change in net sales assuming that foreign currency exchange rates have not changed between the prior and current periods. Net sales are also presented on an operational basis. For the quarter ended December31, 2018, it excludes the impact of foreign exchange, generic competition for U.S. cyclophosphamide and the acquisition of the RECOTHROM and PREVELEAK products. For full year 2018, operational sales also exclude seven months of sales from the Claris Injectables’ (Claris) business acquired in July 2017.

Free cash flow represents operating cash flow less capital expenditures. This measure provides an indication of cash flow that may be available to fund investments in future growth initiatives.

Non-GAAP financial measures may provide a more complete understanding of the Company’s operations and can facilitate a fuller analysis of the Company’s results of operations, particularly in evaluating performance from one period to another and is consistent with how management and the Company’s Board of Directors assesses its performance. Management believes that non-GAAP earnings measures, when used in conjunction with the results presented in accordance with GAAP and the reconciliations to corresponding GAAP financial measures, may enhance an investor’s overall understanding of the Company’s past financial performance and prospects for the future. Accordingly, management uses these non-GAAP measures internally in financial planning, to monitor business unit performance, to assess our performance relative to peers and in some cases, for purposes of determining incentive compensation. This information should be considered in addition to, and not as substitutes for, information prepared in accordance with GAAP.

The Company strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by the Company may differ from similar measures used by other companies, even when similar terms are used to identify such measures.

Item 2.02 Financial Statements and Exhibits.



99.1 Press Release Dated January31, 2019

EX-99.1 2 d699628dex991.htm EX-99.1 EX-99.1   Exhibit 99.1   FOR IMMEDIATE RELEASE Media Contact Steve Brett,…
To view the full exhibit click here

About Baxter International Inc. (NYSE:BAX)

Baxter International Inc., through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures IV solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. The business also provides products and services related to pharmacy compounding, and drug formulation. The Renal business provides products and services to treat end-stage renal disease, or irreversible kidney failure and acute kidney injuries.

An ad to help with our costs